No Data
No Data
MAIA Biotechnology Updates Executive Compensation Packages
MAIA Biotechnology Reports Promising Phase 2 Trial Results
MAIA Biotechnology Announce Efficacy Updates For Phase 2 THIO-101 Trial In Advanced Non-Small Cell Lung Cancer; Median Overall Survival From THIO Treatment Extends To 16.9 Months
Express News | Maia Biotechnology Inc - Sees Opportunity for Accelerated FDA Approval of Thio
Express News | Maia Biotechnology Inc - Third Line Data Shows Median Overall Survival of 16.9 Months
Express News | Maia Biotechnology Announces Positive Efficacy Updates for Phase 2 Thio-101 Trial in Advanced Non-Small Cell Lung Cancer
HannChau : I will not be silent stalker but always will be voice out 'stalker'![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Best Yavo : can I ask what time frames do u look at when trading?
Jaguar8 OP Best Yavo : 1,3,5,15 for active trades
Best Yavo : thank you
MilaDing Best Yavo : When do you usually release Watchlist information?
View more comments...